A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 415 participants.

Also called NCT02332824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 415 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02332824
  • WHO UTN U1111-1161-6858
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02332824. Randomized; quadruple masking; primary purpose treatment. Start 2014-10-16 (actual); primary completion 2016-08-18 (actual). Results posted on 2018-08-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Condition
Type 2 Diabetes Mellitus and Microalbuminuria
Intervention (Drug)
TAK-272
Intervention (Drug)
TAK-272 Placebo
Intervention (Drug)
Candesartan cilexetil
Intervention (Drug)
Candesartan cilexetil Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02332824
Content hash
80df705901ae9e1fd9b30999b63ca25956c03d657972765079f2a86ccf90383e